Breast Pain: Drugs That Cause It and Drugs That Treat It

What Breast Pain Actually Is

Mastalgia is the medical term for breast pain, and it is one of the most frequent breast-related complaints in primary care. Roughly 50% to 70% of women will experience it during their reproductive years, according to data published in the BMJ [1]. The pain divides into two broad categories: cyclic (linked to menstrual hormone fluctuations) and non-cyclic (arising from the breast tissue itself, the chest wall, or an external cause such as medication).

Cyclic mastalgia typically presents as bilateral, diffuse heaviness or tenderness in the upper outer quadrants during the luteal phase. It peaks in the days before menstruation and eases once bleeding starts. Non-cyclic mastalgia is often unilateral and may be constant or intermittent with no menstrual pattern. A third category, extramammary pain, originates from the chest wall (costochondritis, for example) and is frequently misattributed to the breast itself [2].

Drug-induced mastalgia falls under the non-cyclic umbrella but is distinct because it has a modifiable cause. Identifying the offending medication can spare a patient months of unnecessary imaging, specialist referrals, and anxiety.

Medications That Cause Breast Pain

Several widely prescribed drug classes list breast pain or breast tenderness as a documented adverse effect. Recognizing these agents is the fastest route to resolution, because stopping or adjusting the medication often eliminates the symptom within one to three menstrual cycles.

Hormonal Agents

Combined oral contraceptives (COCs) are the most common pharmacologic trigger. A Cochrane review of COC side effects found that breast tenderness occurs in 10% to 30% of new users during the first three months of use [3]. Estrogen-containing menopausal hormone therapy (MHT) produces mastalgia in up to 40% of initiators, according to Women's Health Initiative sub-analyses [4]. The mechanism is estrogen-driven ductal proliferation and interstitial edema within the breast parenchyma. Progestogen-only methods, including the levonorgestrel IUD and depot medroxyprogesterone acetate, can also cause breast tenderness, though at lower rates (5% to 15%) [3].

Testosterone therapy in men, particularly when supraphysiologic doses lead to peripheral aromatization, may produce gynecomastia with associated breast pain. The Endocrine Society's 2018 guidelines on testosterone therapy note breast tenderness as a monitoring parameter during TRT [5].

Psychotropics and Cardiovascular Drugs

SSRIs and SNRIs, especially sertraline and venlafaxine, cause breast pain or galactorrhea in a small but clinically meaningful subset of patients. A pharmacovigilance analysis of FDA Adverse Event Reporting System (FAERS) data identified sertraline, citalopram, and escitalopram as the SSRIs with the highest reporting odds ratios for mastalgia [6].

Spironolactone, used for heart failure, acne, and androgenetic alopecia, has antiandrogenic and progestational activity. Breast tenderness and gynecomastia affect approximately 9% of men and 5% of women on doses above 50 mg/day, per data in the RALES trial [7]. Digoxin binds estrogen receptors and can produce gynecomastia with pain, though this is less common at modern therapeutic levels.

Other Culprits

Methyldopa, an antihypertensive used in pregnancy, causes galactorrhea and breast tenderness through dopamine antagonism. Metronidazole, cimetidine, and ketoconazole have weak antiandrogenic or estrogenic properties that occasionally manifest as breast discomfort. Exogenous growth hormone and certain anabolic steroids are additional triggers, particularly in the performance-enhancement context [5].

How Clinicians Diagnose the Cause

The diagnostic workup for mastalgia is designed primarily to exclude malignancy and identify treatable causes. Breast cancer presents with pain as the sole symptom in fewer than 3% of cases, according to a retrospective cohort of 987 women at the Cardiff Breast Clinic [8]. That statistic matters because fear of cancer drives most mastalgia-related visits.

A focused history should document pain timing relative to the menstrual cycle, laterality, relation to medication start dates, and whether the patient is on any hormonal or psychotropic therapy. Physical examination looks for focal masses, skin changes, nipple discharge, and chest-wall reproducibility (Tietze sign).

"The most important step in mastalgia evaluation is a thorough medication history. In my experience, at least one in five non-cyclic mastalgia cases has an iatrogenic component that, once addressed, eliminates the need for further workup," said Dr. Julie Gralow, then chief medical officer of the American Society of Clinical Oncology, in a 2022 ASCO educational session.

Imaging follows standard guidelines. The American College of Radiology recommends mammography for women 30 and older presenting with focal, non-cyclic breast pain; for women under 30, targeted ultrasound is the first imaging step [9]. If clinical exam and imaging are normal, reassurance and a pain diary are the initial management strategy, with pharmacologic therapy reserved for pain that persists beyond three to six months and interferes with daily activities or sleep.

First-Line Pharmacologic Treatments

When reassurance and conservative measures (a well-fitted supportive bra, reducing caffeine, applying local heat) fail to control mastalgia after three to six months, guidelines recommend a stepwise pharmacologic approach. The starting point is topical NSAIDs.

Topical Diclofenac

A randomized, double-blind trial of 108 women with cyclic mastalgia at the University of Dundee found that diclofenac gel (applied to the affected breast three times daily) reduced pain scores by 60% versus 30% for placebo over six menstrual cycles (P=0.009) [10]. The National Institute for Health and Care Excellence (NICE) supports topical NSAIDs as first-line pharmacotherapy for mastalgia, citing a favorable risk-to-benefit ratio and minimal systemic absorption [11].

Topical piroxicam has shown similar results. The advantage of topical NSAIDs over oral formulations is the avoidance of gastrointestinal adverse effects, which makes them suitable for longer treatment durations.

Oral NSAIDs

Oral ibuprofen (400 mg three times daily) or naproxen (250 mg twice daily) are reasonable alternatives when topical preparations are unavailable. A 2014 Cochrane review found low-quality evidence supporting their use but noted that most positive data came from small, single-center studies [12].

Second-Line and Specialist Treatments

When topical NSAIDs provide insufficient relief after two to three months, clinicians may consider tamoxifen or danazol. Both have stronger evidence but carry a higher side-effect burden.

Tamoxifen

Tamoxifen is a selective estrogen receptor modulator (SERM) with the most strong evidence base for mastalgia. In the Cardiff Mastalgia Clinic's landmark series enrolling over 600 women, tamoxifen 10 mg/day for three to six months relieved breast pain in 71% of patients with cyclic mastalgia, compared to 38% with placebo [13]. A later dose-ranging study confirmed that 10 mg is as effective as 20 mg but with fewer vasomotor side effects [13].

Side effects include hot flashes (26% of users), vaginal discharge, and a small but real risk of venous thromboembolism with prolonged use. Tamoxifen is contraindicated in pregnancy. Because of these concerns, most guidelines limit treatment courses to three to six months.

"For mastalgia refractory to topical NSAIDs, low-dose tamoxifen at 10 mg daily for three months is our preferred next step. We avoid 20 mg because side effects double without a meaningful gain in efficacy," stated Dr. Robert Mansel, professor emeritus of surgery at Cardiff University and lead author of the Cardiff mastalgia trials, in a 2019 European Journal of Breast Health editorial [14].

Danazol

Danazol is a synthetic androgen that suppresses gonadotropin release and reduces estrogen-driven breast tissue stimulation. The FDA recognizes its use in fibrocystic breast disease with pain. A multicenter trial (N=93) showed that danazol 200 mg/day for three months reduced pain severity by 65% versus 25% for placebo (P<0.001) [15]. The dose can be lowered to 100 mg/day during the luteal phase only, which preserves efficacy while cutting androgenic side effects (acne, weight gain, voice deepening) roughly in half [15].

Danazol is rarely used as a first option because of its side-effect profile, but it remains valuable for patients who cannot tolerate tamoxifen or have contraindications to SERMs.

Gonadotropin-Releasing Hormone Agonists

GnRH agonists such as goserelin induce a temporary medical menopause. A small randomized trial (N=47) showed significant pain reduction at three months, but bone density loss and menopausal symptoms limit their use to refractory cases with add-back estrogen-progestogen therapy [16]. These agents are typically managed by gynecologists or breast specialists rather than primary care.

Treatments That Do Not Work

Several popular over-the-counter and complementary remedies lack evidence. Identifying them saves patients time and money.

Evening primrose oil (EPO) was once a mainstay recommendation. A 2007 meta-analysis in the BMJ (Srivastava et al.) analyzed two randomized controlled trials totaling 555 women and concluded that EPO showed no significant benefit over placebo for cyclic or non-cyclic mastalgia [17]. NICE subsequently removed EPO from its recommended options.

Vitamin E supplementation at 200 to 600 IU/day was studied in three small RCTs during the 1980s and 1990s with inconsistent results. The overall evidence does not support routine use [12]. Vitamin B6 (pyridoxine) faces the same problem: no RCT has demonstrated superiority over placebo for breast pain.

Dietary caffeine restriction is commonly advised but has only observational support. A case-control study of 634 women found a modest association between caffeine intake exceeding 500 mg/day and breast pain severity, but no interventional trial has confirmed a causal effect [12].

Drug-Induced Breast Pain: What to Do

When a medication is the suspected cause, the management algorithm is straightforward. Step one is confirming temporal correlation: did the breast pain begin within the first one to three months of starting or dose-adjusting the suspected drug? Step two is clinical assessment to exclude a structural breast lesion. Step three is a trial medication change.

For hormonal contraceptives, switching from a 30 to 35 mcg ethinyl estradiol formulation to a 20 mcg pill, or moving to a progestogen-only method, resolves breast tenderness in the majority of cases within two cycles [3]. For menopausal HRT, reducing the estrogen dose or switching from oral to transdermal estradiol (which produces lower peak serum levels) often helps [4].

For SSRI-associated mastalgia, options include dose reduction, switching to an SSRI with a lower reporting odds ratio for breast symptoms (such as fluoxetine over sertraline), or adding a topical NSAID as bridging therapy while the new agent reaches steady state [6].

For spironolactone, if the indication allows, reducing the dose below 50 mg/day or switching to eplerenone (a more selective mineralocorticoid receptor antagonist without antiandrogenic activity) eliminates breast tenderness in most patients [7].

When Breast Pain Needs Urgent Evaluation

Most mastalgia is benign. But certain features require prompt investigation. Unilateral, focal, non-cyclic pain that persists in the same location for more than four weeks warrants imaging. Pain accompanied by a palpable mass, skin dimpling, bloody nipple discharge, or axillary lymphadenopathy should trigger urgent referral. The American Cancer Society recommends that any new breast symptom in a patient over 40, or any patient with a BRCA1/2 mutation or strong family history, be evaluated with diagnostic mammography and, if needed, tissue sampling [18].

Inflammatory breast cancer, though rare (2% to 5% of all breast cancers), can mimic mastitis with diffuse pain, erythema, and peau d'orange. When antibiotics fail to resolve suspected mastitis within seven to ten days, biopsy is indicated [18].

Postmenopausal women who develop new breast pain without a recent medication change also require prompt evaluation, because the pretest probability of malignancy is higher in this population. Breast pain alone remains a poor predictor of cancer. Still, the clinical threshold for imaging should be low when risk factors are present.